Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.36 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 9/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17992384 | 0.91 | CPB2 (0.36) | CPB2GLSMEN1MITFKMT2A | |
| SCHEMBL21335222 | 0.88 | CPB2 (0.35) | CPB2GLSMEN1MITFKMT2A | |
| SCHEMBL19825813 | 0.88 | CPB2 (0.36) | CPB2MEN1MITFKMT2AKDM1A | |
| SCHEMBL19825861 | 0.88 | CPB2 (0.38) | CPB2MEN1MITFKMT2AKDM1A | |
| SCHEMBL21335156 | 0.85 | CPB2 (0.40) | CPB2KMT2AMETAP2 | |
| SCHEMBL21335165 | 0.83 | CPB2 (0.34) | CPB2KDM1A | |
| SCHEMBL23658150 | 0.82 | CPB2 (0.35) | CPB2MEN1MITFKMT2A | |
| SCHEMBL19825818 | 0.82 | CPB2 (0.35) | CPB2MEN1MITFKMT2A | |
| SCHEMBL18637675 | 0.82 | FNTA (0.41) | CPB2KMT2A | |
| SCHEMBL21335314 | 0.82 | NMT1 (0.38) | CPB2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200188476-A1 | ANTI-MICROBIAL AGENT-POLYMER CONJUGATES AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2020-06-18 | — | — | US | disclosed |
| US-10407467-B2 | Polymyxin derivatives and their use in combination therapy together with different antibiotics | NEW PHARMA LICENCE HOLDINGS LIMITED (MT) | 2019-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200188476-A1 | ANTI-MICROBIAL AGENT-POLYMER CONJUGATES AND METHODS OF USE THEREOF | DDOST, MGAM, MSN | CPB2 1548/4885GLS 939/4885MEN1 3883/4885 |
| US-10407467-B2 | Polymyxin derivatives and their use in combination therapy together with different antibiotics | MRPS18A, MRPL21, RRP1B | CPB2 1537/4885GLS 1251/4885MEN1 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.